MHRA (Medicines & Healthcare Products Regulatory Agency) puts weight behind Boston stent recall:
This article was originally published in Clinica
The number of products affected in the UK by the global recall of certain batches of Boston Scientific's Taxus Express2 paclitaxel-eluting stent system and Express2 bare metal stent system are 26,000 and 15,000, respectively. So says the device alert issued by the Medicines and Healthcare products Regulatory Agency (MHRA) on July 23. The company has said that 85,000 and 11,000 units, respectively, were being recalled worldwide. UK healthcare providers have been issued with a July 29 deadline for receiving a recall notification from Boston. Failure to receive this will require that all products of these types be returned to the manufacturer.
You may also be interested in...
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.
Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.
Singapore recalls trigger international reaction as metformin is added to growing list of chronic medications found to contain NDMA.